Data from a phase IIb study exploring the safety and tolerability of enzalutamide plus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) show that this combination is safe in these patients, although the majority of patients experience neutropenia (86.4%) and fatigue (77.3%) as treatment-related adverse events. Almost all patients who received combination therapy had decreased serum PSA levels. These findings merit further investigation in a larger cohort of patients.
References
Morris, M. J. et al. Phase Ib study of enzalutamide in combination with docetaxel in men with metastatic castration-resistant prostate cancer. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-15-2638 (2016)
Rights and permissions
About this article
Cite this article
Sidaway, P. Enzalutamide plus docetaxel tested in mCRPC. Nat Rev Urol 13, 182 (2016). https://doi.org/10.1038/nrurol.2016.39
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.39